evidence: A significant post-treatment increase in VEGF levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL)
intervention: chemoimmunotherapy with bevacizumab (PCR-B)
comparator: chemoimmunotherapy without bevacizumab (PCR)
outcome: PFS and TFS by IGHV mutational status